Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.62 |
| ▸ | NOS3 | P29474 | 1/20 | 0.62 |
| ▸ | NOS2 | P35228 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | CFD | P00746 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.41 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442197 | 1.00 | NOS1 (0.62) | NOS1NOS3NOS2F2CFD | |
| SCHEMBL1202291 | 0.85 | NOS1 (0.62) | NOS1NOS3NOS2F2CFD | |
| SCHEMBL29891596 | 0.85 | NOS1 (0.62) | NOS1NOS3NOS2F2CFD | |
| SCHEMBL7422358 | 0.78 | F2 (0.56) | NOS1NOS3NOS2F2CFD | |
| SCHEMBL12324556 | 0.78 | F2 (0.56) | NOS1NOS3NOS2F2CFD | |
| SCHEMBL31607092 | 0.78 | F2 (0.56) | F2CFDMAOAMAOBKIF11 | |
| SCHEMBL31607095 | 0.78 | F2 (0.56) | F2CFDMAOAMAOBKIF11 | |
| SCHEMBL1202554 | 0.78 | F2 (0.56) | F2CFDMAOAMAOBALDH1A1 | |
| SCHEMBL625761 | 0.78 | LMNA (0.62) | NOS1NOS3NOS2F2CFD | |
| SCHEMBL30549739 | 0.78 | F2 (0.56) | F2CFDMAOAMAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118727475-A | Room temperature salt-free rapid reactive dyeing and recycling method suitable for cellulose fibers | 绍兴劲草化工有限公司 | 2024-10-01 | — | — | CN | claimed |
| US-4728673-A | BLOWING AGENT OF ISATOIC ANHYDRIDE DERIVATIVE IN PRESCENT OF NEUTRAL SALT | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-01 | — | — | US | claimed |
| EP-4727923-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4551208-A1 | PHARMACEUTICAL COMPOSITION, METHODS OF USE THEREOF FOR TREATING COCAINE ADDICTION, AND NOVEL USE OF HAUSP K444R POINT MUTANT MOUSE | Pharwar Biotechnology, Inc. Pte. Ltd. (SG) | 2025-05-14 | — | — | EP | disclosed |
| US-20250091982-A1 | Pharmaceutical Composition, Methods of Use Thereof for Treating Cocaine Addiction, and Novel Use of Hausp K444R Point Mutant Mouse | PHARWAR BIOTECHNOLOGY, INC. PTE. LTD. (SG) | 2025-03-20 | — | — | US | disclosed |
| EP-4514804-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | Viscient Bio, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| US-6884801-B1 | Imidazoline derivatives as alpha-1A adrenoceptor ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1175406-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | disclosed |
| EP-0234219-B1 | PROCESS FOR FOANING ESTER AND/OR CARBONATE GROUPS CONTAINING THERMOPLASTIC RESINS | BAYER AG (DE) | 1990-04-18 | — | — | EP | disclosed |
| EP-0135367-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1988-03-16 | — | — | EP | disclosed |
| US-4728673-A | BLOWING AGENT OF ISATOIC ANHYDRIDE DERIVATIVE IN PRESCENT OF NEUTRAL SALT | BAYER AKTIENGESELLSCHAFT (DE) | 1988-03-01 | — | — | US | disclosed |
| EP-0234219-A2 | Process for foaning ester and/or carbonate groups containing thermoplastic resins | BAYER AG (DE) | 1987-09-02 | — | — | EP | disclosed |
| US-4659718-A | VASODILATION | THE BOOTS COMPANY PLC (GB) | 1987-04-21 | — | — | US | disclosed |
| EP-0135367-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091982-A1 | Pharmaceutical Composition, Methods of Use Thereof for Treating Cocaine Addiction, and Novel Use of Hausp K444R Point Mutant Mouse | CES2, HDAC6, CHRNB4 | NOS1 1749/4885NOS3 2016/4885NOS2 2300/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | NOS1 2212/4885NOS3 2090/4885NOS2 2079/4885 |
| US-20260098012-A1 | TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA | CD47, SLC11A2, G6PD | NOS1 793/4885NOS3 537/4885NOS2 890/4885 |
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | NOS1 1545/4885NOS3 773/4885NOS2 230/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | NOS1 4234/4885NOS3 4735/4885NOS2 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.